FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2934693265> ?p ?o ?g. }

• W2934693265 endingPage "4127" @default.
• W2934693265 startingPage "4127" @default.
• W2934693265 abstract "Abstract Background: Despite mycosis fungoides (MF) and Sezary syndrome (SS) comprising the most common forms of cutaneous T cell lymphoma, the pathophysiology underlying these disorders remains poorly understood. Consequently, current prognostic guidelines based on disease spread exhibit wide variations in clinical outcome within each stage, underscoring an urgent need for novel approaches to MF/SS disease evaluation. A growing body of research suggests that systemic immune dysregulation represents an early, cardinal feature of MF/SS. We hypothesized that tracking this immune dysfunction in conjunction with disease spread may generate important pathophysiologic and prognostic information for patients. We focused on myeloid-derived suppressor cells (MDSCs), a recently discovered population of immunosuppressive innate immune cells related to neutrophils and monocytes, because their expansion in numerous solid tumor settings have correlated reliably with poor patient outcomes. Whether MF/SS augments circulating MDSC abundance remains unexplored, prompting us to evaluate whether this could serve as a marker for disease progression and treatment response. Methods: We used multiparametric flow cytometry to analyze the frequency and immunophenotype of MDSCs from the peripheral blood of 15 healthy donors and 30 patients with MF/SS. Patients at varying stages of MF/SS disease progression and treatment were included in the study. We defined granulocytic MDSCs (G-MDSCs) as cells positive for CD15, CD11b, and the recently discovered surface marker LOX-1, and negative for CD14. Monocytic MDSCs (M-MDSCs) were defined as cells positive for CD14 and CD11b, negative for CD15, and low/negative for HLA-DR. Each patient sample also underwent flow cytometry evaluating for circulating neoplastic T cells. These results were correlated with each participant's other hematologic parameters and clinical information through manual chart review. Results: We found that healthy donors harbored no quantifiable circulating MDSCs of either monocytic or granulocytic lineage, a result in keeping with previous studies. In contrast, MF/SS patients exhibited robust, statistically significant increases in the frequencies of both G-MDSCs and, to a lesser extent, M-MDSCs. G-MDSCs exceeded 20% of all CD15-positive cells in some patients. When patients were stratified by MF/SS clinical stage, those with more advanced disease displayed significantly higher G-MDSC abundance than early-stage patients. G-MDSC frequency was positively correlated with circulating CD4+ CD26- T cell counts often used in evaluating Sezary syndrome (R2 = 0.498; p < 0.0001). However, patients with early, skin-restricted disease also showed statistically significant increases in circulating G-MDSCs compared to healthy controls. This suggested that G-MDSC expansion may serve as a sensitive, blood-based disease marker even in the absence of systemic involvement by neoplasia. Patients who underwent recent treatment exhibited variable G-MDSC counts in the peripheral blood that were lower than in similar untreated patients on average. Serial measurements for two patients enrolled in a clinical trial for dual phosphoinositide 3-kinase and histone deacetylase inhibition revealed that G-MDSC frequencies markedly decreased over the course of treatment, mirroring the decrements of aberrant T cells circulating in the blood. Conclusion: These findings provide clear evidence of G-MDSC expansion in the peripheral blood of MF/SS patients that begins in early/locally restricted disease, grows with disease progression, and responds to systemic therapy. Such immunometric assays may illuminate a novel source of staging and prognostic information and may permit less invasive disease monitoring than current methods require. Disclosures No relevant conflicts of interest to declare." @default.
• W2934693265 created "2019-04-11" @default.
• W2934693265 creator A5027464923 @default.
• W2934693265 creator A5039168471 @default.
• W2934693265 creator A5040136024 @default.
• W2934693265 date "2018-11-29" @default.
• W2934693265 modified "2023-09-27" @default.
• W2934693265 title "Circulating Myeloid-Derived Suppressor Cells Reflect Mycosis Fungoides/Sezary Syndrome Disease Stage and Response to Treatment" @default.
• W2934693265 doi "https://doi.org/10.1182/blood-2018-99-120344" @default.
• W2934693265 hasPublicationYear "2018" @default.
• W2934693265 type Work @default.
• W2934693265 sameAs 2934693265 @default.
• W2934693265 citedByCount "1" @default.
• W2934693265 countsByYear W29346932652020 @default.
• W2934693265 crossrefType "journal-article" @default.
• W2934693265 hasAuthorship W2934693265A5027464923 @default.
• W2934693265 hasAuthorship W2934693265A5039168471 @default.
• W2934693265 hasAuthorship W2934693265A5040136024 @default.
• W2934693265 hasBestOaLocation W29346932651 @default.
• W2934693265 hasConcept C10205521 @default.
• W2934693265 hasConcept C121608353 @default.
• W2934693265 hasConcept C126322002 @default.
• W2934693265 hasConcept C142724271 @default.
• W2934693265 hasConcept C179185449 @default.
• W2934693265 hasConcept C196166836 @default.
• W2934693265 hasConcept C203014093 @default.
• W2934693265 hasConcept C2776804306 @default.
• W2934693265 hasConcept C2777756187 @default.
• W2934693265 hasConcept C2778513237 @default.
• W2934693265 hasConcept C2779134260 @default.
• W2934693265 hasConcept C2779282312 @default.
• W2934693265 hasConcept C2779338263 @default.
• W2934693265 hasConcept C28328180 @default.
• W2934693265 hasConcept C2908647359 @default.
• W2934693265 hasConcept C54355233 @default.
• W2934693265 hasConcept C553184892 @default.
• W2934693265 hasConcept C55721878 @default.
• W2934693265 hasConcept C71924100 @default.
• W2934693265 hasConcept C86803240 @default.
• W2934693265 hasConcept C8891405 @default.
• W2934693265 hasConcept C99454951 @default.
• W2934693265 hasConceptScore W2934693265C10205521 @default.
• W2934693265 hasConceptScore W2934693265C121608353 @default.
• W2934693265 hasConceptScore W2934693265C126322002 @default.
• W2934693265 hasConceptScore W2934693265C142724271 @default.
• W2934693265 hasConceptScore W2934693265C179185449 @default.
• W2934693265 hasConceptScore W2934693265C196166836 @default.
• W2934693265 hasConceptScore W2934693265C203014093 @default.
• W2934693265 hasConceptScore W2934693265C2776804306 @default.
• W2934693265 hasConceptScore W2934693265C2777756187 @default.
• W2934693265 hasConceptScore W2934693265C2778513237 @default.
• W2934693265 hasConceptScore W2934693265C2779134260 @default.
• W2934693265 hasConceptScore W2934693265C2779282312 @default.
• W2934693265 hasConceptScore W2934693265C2779338263 @default.
• W2934693265 hasConceptScore W2934693265C28328180 @default.
• W2934693265 hasConceptScore W2934693265C2908647359 @default.
• W2934693265 hasConceptScore W2934693265C54355233 @default.
• W2934693265 hasConceptScore W2934693265C553184892 @default.
• W2934693265 hasConceptScore W2934693265C55721878 @default.
• W2934693265 hasConceptScore W2934693265C71924100 @default.
• W2934693265 hasConceptScore W2934693265C86803240 @default.
• W2934693265 hasConceptScore W2934693265C8891405 @default.
• W2934693265 hasConceptScore W2934693265C99454951 @default.
• W2934693265 hasIssue "Supplement 1" @default.
• W2934693265 hasLocation W29346932651 @default.
• W2934693265 hasOpenAccess W2934693265 @default.
• W2934693265 hasPrimaryLocation W29346932651 @default.
• W2934693265 hasRelatedWork W1762077205 @default.
• W2934693265 hasRelatedWork W1868326946 @default.
• W2934693265 hasRelatedWork W1990381878 @default.
• W2934693265 hasRelatedWork W2090744478 @default.
• W2934693265 hasRelatedWork W2102731056 @default.
• W2934693265 hasRelatedWork W2253972308 @default.
• W2934693265 hasRelatedWork W2561781137 @default.
• W2934693265 hasRelatedWork W2934693265 @default.
• W2934693265 hasRelatedWork W4295817692 @default.
• W2934693265 hasRelatedWork W4313350083 @default.
• W2934693265 hasVolume "132" @default.
• W2934693265 isParatext "false" @default.
• W2934693265 isRetracted "false" @default.
• W2934693265 magId "2934693265" @default.
• W2934693265 workType "article" @default.